APP E590D突变增加了Aβ和Aη的生成,并加剧了病症
Tian Liu1, Liam Wetzel1, David Roy1
1Department of Pathology, School of Medicine, Case Western Reserve University, Cleveland, 44106 OH USA.
概括
APP695E590D突变通过增加粉样β (Aβ) 和粉样β (Aη) 来加速阿尔茨海默病 (AD). 这种罕见的突变还会使病理和神经炎症恶化,影响AD的进展.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 分子生物学分子生物学
背景情况:
- 从粉样蛋白前体蛋白 (APP) 处理中积累的粉样蛋白β (Aβ) 是阿尔茨海默病 (AD) 的关键.
- 由于其罕见,APP695E590D突变在AD病变发生过程中的作用尚不清楚.
研究的目的:
- 描述APP695E590D突变对APP代谢物和病的影响.
- 在细胞和动物模型中研究APP695E590D突变的致病性.
主要方法:
- 评估多种APP代谢物,包括Aβ和Aη.
- 在细胞模型中评估的播种和聚合.
- 在tauP301S小鼠中分析酸病理和神经炎症.
主要成果:
- APP695E590D通过内细胞β-分泌酶处理增加了Aβ.
- APP695E590D提高了协同毒性Aη的水平.
- 这种突变促进病,加剧酸病理和神经炎症.
结论:
- APP695E590D通过增加Aβ和Aη的产生,独特地影响AD病理.
- 这种突变加速了病变,突出了它在阿尔茨海默病发展中的重要性.
- 了解APP695E590D为阿尔茨海默病的新型治疗点提供了洞察力.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
61
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
61
Amyloid Fibrils
12.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.5K


